Proportion of mutations that make up TDR* 7-27% resistance to protease inhibitors 23-43% thymidine analogue mutations (TAMs, encoding for resistance to zidovudine and stavudine) 40-60% resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs) [1] HIV Prevalence 7.1%-8.4% between 2005 and 2009 [2,3] JCRC catchment area population 300,000-372,000 in 2012 Local Data * The M184V (associated with resistance to lamivudine or emtricitabine) and K65R mutations (associated with tenofovir resistance) were also included in the model, but were not calibrated specifically to the model as these mutations were not observed in the PASER-Surveillance data [1] . Figure S4 . Yearly transmitted drug resistance prevalence separated out by the following resistance mutation or class: a TAM mutation, M184V mutation, K65R mutation, or resistance to NNRTIs, PIs. Panel A is when treatment is initiated at a CD4 count <350 cells/µl, Panel B at CD4 <500 cells/µl, and Panel C is when treatment is initiated immediately. Figure S5 . One-way sensitivity analyses of the incremental cost-effectiveness of increasing use of second-line treatment at three different treatment initiation thresholds over 10 years.
This diagram summarizes the results of a series of one-way sensitivity analyses on the incremental costeffectiveness of increasing use of second-line treatment at three different treatment initiation thresholds. Each horizontal bar represents the full range of cost-effectiveness ratios produced by varying a given model parameter across its plausible range. The vertical dotted lines represent the incremental cost-effectiveness ratio at each treatment initiation threshold ($1,612 per quality adjusted life year for immediate treatment, $2,234 per quality adjusted life year gained when treating at CD4 <500 cells/µl, and $1,925 per quality adjusted life year gained when treating at CD4 <350 cells/µl). The gray area represents the values that can be considered cost-effective.
